ライフサイエンスコーパス: flu-like symptom

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 stly of mild and transient injection site or flu-like symptoms.

2 effects were limited primarily to transient flu-like symptoms.

3 ing fever, respiratory distress, nausea, and flu-like symptoms.

4 city was manageable, consisting primarily of flu-like symptoms.

5 mogeneous or central redness and nonspecific flu-like symptoms.

6 r function, and a single patient with severe flu-like symptoms.

7 r toxicities during the first cycle included flu-like symptoms (21% of patients), fatigue (6% of pati

8 (78% with mipomersen, 31% with placebo) and flu-like symptoms (34% with mipomersen, 21% with placebo

9 transient post-DC infusion chills (38%) and flu-like symptoms (84%), dermatitis (64%), hepatitis (13

10 aise after the first infliximab infusion and flu-like symptoms after the second one.

11 ute illness in humans, producing nonspecific flu-like symptoms and a biphasic fever in approximately

12 who presented with a 3-wk history of fever, flu-like symptoms and abdominal pain.

13 a zoonotic disease that presents with acute flu-like symptoms and can result in chronic life-threate

14 ine encephalitis virus (VEEV), which elicits flu-like symptoms and encephalitis in humans, with an es

15 ssa hemorrhagic fever in humans, begins with flu-like symptoms and leads to death approximately 2 wee

16 ptive transfer to be associated with grade I flu-like symptoms and malaise.

17 Treatment was well tolerated with minimal flu-like symptoms and no significant hematologic changes

18 Fever, flu-like symptoms, and fatigue occurred significantly mo

19 mon nonhematologic toxicities were asthenia, flu-like symptoms, and fluid retention.

20 nts), hematologic toxicity (seven patients), flu-like symptoms, and infection (five patients each).

21 icities related to virus administration were flu-like symptoms, emesis, and abdominal pain.

22 Adverse events consisted of flu-like symptoms (fever/chills, nausea/vomiting, and my

23 grade 1 to 2 pain at the injection site and flu-like symptoms following IDI, some patients receiving

24 th D+G consisted largely of mild to moderate flu-like symptoms, including headache and fever, and occ

25 mplications of IFNalpha2b included transient flu-like symptoms (n = 3), corneal epithelial defect (n

26 Common toxicities included flu-like symptoms, nausea, and emesis.

27 included mild to moderate mucocutaneous and flu-like symptoms; occasional significant fatigue (grade

28 rhagic fever characterized by rapid onset of flu-like symptoms often followed by hemorrhagic manifest

29 LD] or symptomatic EBV infection, defined as flu-like symptoms or infectious mononucleosis).

30 The most common adverse events included flu-like symptoms, pruritus, and rash.

31 olled and were stratified by the presence of flu-like symptoms (such as fever, chills, headache, mala

32 The most common adverse events were flu-like symptoms that occurred principally after the fi

33 ponsible for Q fever, a febrile illness with flu-like symptoms that often goes undiagnosed.

34 Acute human Q fever is characterized by flu-like symptoms that, in some cases, can result in a p

35 al conditions in children, ranging from mild flu-like symptoms to coma and death.

36 Finally, flu-like symptoms were lower in the intervention group.

37 Flu-like symptoms were reported in one patient but not c

38 s of cytomegalovirus (CMV) infection include flu-like symptoms with fever, diarrhea, leukopenia, and

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。